Products Everolimus + ONC201
Everolimus + ONC201 Phase 3 Recruiting ⚡ Active Interest: 44/100
Diffuse Intrinsic Pontine Glioma
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
Sep 29, 2022 → Sep 1, 2031
About Everolimus + ONC201 Everolimus + ONC201 is a phase 3 stage product being developed by Jazz Pharmaceuticals for Diffuse Intrinsic Pontine Glioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05476939. Target conditions include Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered.
What happened to similar drugs? 1 of 20 similar drugs in Diffuse Intrinsic Pontine Glioma were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT05476939 Phase 3 Recruiting Sep 29, 2022 Sep 1, 2031 Diffuse Intrinsic Pontine Glioma
Product Company Stage Hype Score IVA337 + Placebo Inventiva Phase 2 Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Eli Lilly Phase 2 rituximab Celltrion Phase 1 YM155 Astellas Pharma Phase 2 enzastaurin + gemcitabine + rituximab + oxaliplatin Eli Lilly Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Johnson & Johnson Phase 2 VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Johnson & Johnson Phase 2 Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine AbbVie Phase 3 ABBV-525 AbbVie Phase 1 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab AbbVie Phase 1/2 Copanlisib + Venetoclax AbbVie Phase 1/2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 Epcoritamab + Lenalidomide AbbVie Phase 2 Venetoclax + Selinexor AbbVie Phase 1 Epcoritamab AbbVie Phase 1 Loncastuximab Tesirine and Epcoritamab AbbVie Phase 2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 bendamustine + navitoclax + rituximab AbbVie Phase 2 Epcoritamab AbbVie Phase 2 Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomide AbbVie Phase 1/2